Pharmacotherapy of anaemia in cancer patients.
Anaemia is a common complication of cancer. The incidence is variable and depends on several factors. A linear correlation between haemoglobin levels and quality of life (QOL) parameters has been found. Erythropoiesis is a finely regulated responsive process and erythropoietin (EPO) is the most important factor influencing progenitor cell proliferation. Impaired EPO production is mediated by inflammatory cytokines liberated in cancer patients. For this reason, EPO has been proposed as an alternative to blood transfusions, which involve many hazards. EPO treatment has been found to be effective in preventing anaemia and reducing the need for blood transfusions, although it would be useful to identify high-risk patient subgroups who would benefit most from this expensive treatment.
Mercadante
S
S
Pain Relief and Palliative Care Unit, La Maddalena Clinic for Cancer, Palermo, Italy. mercadsa@tin.it
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology* / Q000628:therapy; D001803:Blood Transfusion; D004921:Erythropoietin / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications* / Q000532:radiotherapy / Q000601:surgery; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin